Nifty
:
15746.50
Sensex
:
52574.46
63.15 (0.40%)
230.01 (0.44%)
Nifty
Sensex
:
:
15746.50
52574.46
63.15 (0.40%)
230.01 (0.44%)

Jubilant Pharmova Ltd.

Chemicals

Rating :
49/99

BSE: 530019 | NSE: JUBLPHARMA

NSE BSE
747.25
21-Jun-2021
  • Open
  • High
  • Low
  • Previous Close
  •  730.00
  •  764.95
  •  726.60
  •  733.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  415682
  •  3123.25
  •  764.95
  •  0.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 11,700.79
  • 14.00
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 14,929.14
  • 0.68%
  • 2.47

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.68%
  • 3.73%
  • 16.07%
  • FII
  • DII
  • Others
  • 25.69%
  • 0.78%
  • 3.05%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.26
  • 9.75
  • 6.79

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.17
  • 9.32
  • 5.10

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.61
  • 18.05
  • 11.80

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.04
  • 15.69
  • 14.42

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.99
  • 2.44
  • 2.02

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.53
  • 8.93
  • 7.62

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
1,579.78
1,568.54
0.72%
1,771.34
1,517.98
16.69%
2,374.89
2,265.93
4.81%
1,892.92
2,181.86
-13.24%
Expenses
1,205.16
1,130.82
6.57%
1,278.58
1,107.56
15.44%
1,888.71
1,797.48
5.08%
1,590.70
1,747.26
-8.96%
EBITDA
374.62
437.72
-14.42%
492.76
410.42
20.06%
486.18
468.45
3.78%
302.22
434.60
-30.46%
EBIDTM
23.71%
27.91%
27.82%
27.04%
20.47%
20.67%
15.97%
19.92%
Other Income
6.69
17.30
-61.33%
3.59
3.22
11.49%
7.28
12.26
-40.62%
8.13
9.70
-16.19%
Interest
43.34
46.96
-7.71%
46.37
48.83
-5.04%
63.95
71.64
-10.73%
75.95
72.58
4.64%
Depreciation
86.24
98.07
-12.06%
95.94
83.54
14.84%
115.84
116.84
-0.86%
112.30
102.69
9.36%
PBT
241.39
309.99
-22.13%
343.15
248.33
38.18%
313.67
292.23
7.34%
122.10
269.03
-54.61%
Tax
83.06
97.73
-15.01%
121.16
90.18
34.35%
89.55
42.84
109.03%
34.09
84.05
-59.44%
PAT
158.33
212.26
-25.41%
221.99
158.15
40.37%
224.12
249.39
-10.13%
88.01
184.98
-52.42%
PATM
10.02%
13.53%
12.53%
10.42%
9.44%
11.01%
4.65%
8.48%
EPS
13.44
16.35
-17.80%
19.46
12.77
52.39%
14.06
15.66
-10.22%
5.52
11.61
-52.45%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
7,618.93
9,154.41
9,110.82
7,517.84
5,861.43
5,749.13
5,826.25
5,803.36
5,165.95
4,303.13
3,445.62
Net Sales Growth
1.12%
0.48%
21.19%
28.26%
1.95%
-1.32%
0.39%
12.34%
20.05%
24.89%
 
Cost Of Goods Sold
2,317.73
3,140.58
3,521.84
2,862.51
2,002.74
2,116.20
2,663.02
2,438.46
2,062.85
1,618.87
1,339.68
Gross Profit
5,301.20
6,013.84
5,588.98
4,655.33
3,858.69
3,632.94
3,163.23
3,364.90
3,103.10
2,684.26
2,105.95
GP Margin
69.58%
65.69%
61.34%
61.92%
65.83%
63.19%
54.29%
57.98%
60.07%
62.38%
61.12%
Total Expenditure
5,963.15
7,207.34
7,371.81
5,999.45
4,516.14
4,502.19
5,124.71
4,782.37
4,097.81
3,412.94
2,880.76
Power & Fuel Cost
-
473.80
466.38
424.91
333.66
366.71
393.04
389.74
356.73
286.89
224.04
% Of Sales
-
5.18%
5.12%
5.65%
5.69%
6.38%
6.75%
6.72%
6.91%
6.67%
6.50%
Employee Cost
-
2,127.68
1,925.96
1,555.88
1,230.93
1,125.09
1,090.28
1,105.17
962.58
836.36
718.54
% Of Sales
-
23.24%
21.14%
20.70%
21.00%
19.57%
18.71%
19.04%
18.63%
19.44%
20.85%
Manufacturing Exp.
-
602.62
552.26
485.98
428.84
436.46
432.40
405.14
360.48
329.75
284.66
% Of Sales
-
6.58%
6.06%
6.46%
7.32%
7.59%
7.42%
6.98%
6.98%
7.66%
8.26%
General & Admin Exp.
-
488.39
540.75
354.56
280.98
256.23
302.28
264.23
208.35
200.72
195.72
% Of Sales
-
5.34%
5.94%
4.72%
4.79%
4.46%
5.19%
4.55%
4.03%
4.66%
5.68%
Selling & Distn. Exp.
-
292.70
267.70
247.85
185.79
135.54
203.98
160.04
123.28
111.85
90.92
% Of Sales
-
3.20%
2.94%
3.30%
3.17%
2.36%
3.50%
2.76%
2.39%
2.60%
2.64%
Miscellaneous Exp.
-
81.58
96.92
67.76
53.20
65.96
39.72
19.59
23.53
28.50
90.92
% Of Sales
-
0.89%
1.06%
0.90%
0.91%
1.15%
0.68%
0.34%
0.46%
0.66%
0.79%
EBITDA
1,655.78
1,947.07
1,739.01
1,518.39
1,345.29
1,246.94
701.54
1,020.99
1,068.14
890.19
564.86
EBITDA Margin
21.73%
21.27%
19.09%
20.20%
22.95%
21.69%
12.04%
17.59%
20.68%
20.69%
16.39%
Other Income
25.69
47.43
35.74
40.03
24.86
13.37
42.45
19.06
29.87
31.48
17.24
Interest
229.61
287.41
219.81
284.28
341.11
371.35
367.61
337.11
310.93
238.23
119.99
Depreciation
410.32
461.93
370.90
415.05
291.40
346.74
287.95
281.17
253.79
220.65
180.10
PBT
1,020.31
1,245.17
1,184.04
859.08
737.64
542.22
88.43
421.78
533.29
462.79
282.02
Tax
327.86
312.29
326.80
224.66
163.02
155.40
80.48
69.64
152.36
68.41
13.37
Tax Rate
32.13%
25.80%
36.16%
26.15%
22.10%
28.66%
199.55%
33.60%
44.66%
59.95%
5.56%
PAT
692.45
898.24
574.46
642.81
575.66
391.83
-57.76
109.04
152.73
14.56
229.72
PAT before Minority Interest
692.71
898.24
577.01
634.42
574.63
386.82
-40.16
137.64
188.78
45.69
227.23
Minority Interest
0.26
0.00
-2.55
8.39
1.03
5.01
-17.60
-28.60
-36.05
-31.13
2.49
PAT Margin
9.09%
9.81%
6.31%
8.55%
9.82%
6.82%
-0.99%
1.88%
2.96%
0.34%
6.67%
PAT Growth
-13.96%
56.36%
-10.63%
11.66%
46.92%
-
-
-28.61%
948.97%
-93.66%
 
EPS
43.47
56.39
36.06
40.35
36.14
24.60
-3.63
6.84
9.59
0.91
14.42

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
5,603.88
4,808.92
4,086.53
3,436.04
2,966.26
2,453.52
2,626.51
2,476.12
2,257.03
2,172.27
Share Capital
15.93
15.93
15.58
15.57
15.54
15.93
15.45
15.93
15.93
15.93
Total Reserves
5,587.95
4,792.94
4,070.78
3,419.98
2,950.72
2,437.59
2,611.07
2,460.19
2,241.10
2,156.34
Non-Current Liabilities
4,087.52
4,420.21
3,417.47
3,826.06
3,347.13
4,036.15
2,184.95
3,004.85
3,224.12
3,048.25
Secured Loans
728.92
811.65
729.88
1,581.96
2,620.41
3,316.29
1,716.67
1,708.74
2,839.47
2,435.91
Unsecured Loans
3,010.76
3,431.24
2,317.93
1,923.07
392.79
375.00
0.22
760.06
0.45
400.61
Long Term Provisions
150.75
114.35
107.08
80.69
70.31
67.04
219.53
237.96
169.70
39.87
Current Liabilities
2,619.01
2,089.73
2,004.69
1,684.04
2,464.44
2,129.16
3,894.41
2,778.35
2,212.79
2,269.67
Trade Payables
1,090.27
1,020.13
1,136.16
749.49
612.12
721.19
718.14
647.13
836.98
517.43
Other Current Liabilities
674.21
473.57
505.87
572.70
951.43
793.31
1,731.20
898.00
499.55
465.94
Short Term Borrowings
649.89
499.71
244.85
255.60
748.97
517.17
1,187.83
1,131.39
767.07
883.03
Short Term Provisions
204.64
96.31
117.81
106.24
151.93
97.49
257.25
101.84
109.18
403.28
Total Liabilities
12,310.41
11,318.96
9,457.17
8,898.75
8,739.70
8,618.83
8,863.81
8,370.86
7,762.89
7,532.00
Net Block
6,339.97
5,648.38
5,400.55
5,106.73
5,104.42
4,911.33
5,098.78
4,967.46
4,460.18
3,991.05
Gross Block
7,982.83
6,905.50
6,288.86
5,672.38
5,390.82
7,362.10
7,330.63
6,870.15
6,084.09
5,163.28
Accumulated Depreciation
1,642.85
1,257.12
888.31
565.66
286.40
2,450.76
2,231.85
1,902.69
1,623.92
1,172.22
Non Current Assets
7,272.06
6,734.16
6,267.41
5,950.63
5,864.37
5,904.29
5,935.78
5,809.80
5,465.57
4,940.25
Capital Work in Progress
768.39
901.43
670.97
683.78
611.32
596.60
472.39
436.89
685.55
666.71
Non Current Investment
69.36
115.11
123.52
102.71
85.43
39.50
33.99
25.61
19.20
32.75
Long Term Loans & Adv.
86.81
68.59
71.79
56.32
62.67
327.17
328.42
379.47
299.86
249.18
Other Non Current Assets
7.53
0.66
0.58
1.08
0.53
29.68
2.21
0.37
0.79
0.55
Current Assets
5,038.35
4,584.80
3,189.76
2,948.12
2,875.32
2,714.54
2,928.03
2,561.06
2,297.32
2,591.75
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,845.38
1,417.39
1,391.39
1,220.40
1,203.10
1,235.33
1,341.42
1,116.18
1,020.22
691.28
Sundry Debtors
1,293.22
1,271.55
1,130.76
1,005.30
950.50
819.27
805.87
708.54
652.69
520.45
Cash & Bank
1,399.87
1,370.41
248.79
459.63
344.58
394.34
479.53
356.05
266.82
1,045.14
Other Current Assets
499.88
485.64
373.06
225.73
377.13
265.59
301.21
380.29
357.59
334.88
Short Term Loans & Adv.
41.33
39.80
45.75
37.06
133.06
144.56
136.04
182.01
256.70
217.50
Net Current Assets
2,419.34
2,495.07
1,185.06
1,264.08
410.88
585.38
-966.38
-217.29
84.53
322.08
Total Assets
12,310.41
11,318.96
9,457.17
8,898.75
8,739.69
8,618.83
8,863.81
8,370.86
7,762.89
7,532.00

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,542.94
1,121.51
1,303.20
1,268.49
1,098.89
783.26
772.27
969.90
707.17
389.75
PBT
1,210.53
903.81
859.08
737.64
542.22
40.32
207.28
341.14
114.11
240.59
Adjustment
760.74
861.53
687.81
637.90
737.89
725.84
756.60
752.36
795.44
318.42
Changes in Working Capital
-179.67
-300.53
14.15
36.88
-133.16
96.40
-110.70
-4.04
-136.91
-84.14
Cash after chg. in Working capital
1,791.60
1,464.82
1,561.04
1,412.42
1,146.96
862.57
853.18
1,089.46
772.64
474.88
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-248.66
-343.31
-257.84
-143.94
-48.07
-79.31
-80.91
-119.56
-65.47
-85.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-327.00
-1,011.84
-617.70
-450.39
-312.53
-343.33
-174.42
-499.72
-594.31
-352.15
Net Fixed Assets
-241.66
-305.67
-147.58
-115.33
785.60
1,162.43
-166.96
-286.05
-434.15
-275.33
Net Investments
-0.14
-57.59
3.34
-0.39
57.01
239.81
-27.56
-18.79
-95.66
5.14
Others
-85.20
-648.58
-473.46
-334.67
-1,155.14
-1,745.57
20.10
-194.88
-64.50
-81.96
Cash from Financing Activity
-1,050.37
657.43
-901.13
-685.87
-842.75
-502.69
-414.41
-449.76
-888.82
608.21
Net Cash Inflow / Outflow
165.56
767.10
-215.63
132.22
-56.38
-62.76
183.44
20.41
-775.95
645.81
Opening Cash & Equivalents
1,005.40
244.18
456.44
339.27
391.64
473.49
279.65
263.08
1,041.15
498.27
Closing Cash & Equivalent
1,230.81
1,005.40
244.18
456.44
339.27
391.63
473.49
279.65
263.08
1,041.15

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
351.83
301.93
262.33
220.61
190.90
154.04
170.07
155.46
141.70
136.38
ROA
7.60%
5.55%
6.91%
6.52%
4.46%
-0.46%
1.60%
2.34%
0.60%
3.17%
ROE
17.25%
12.97%
16.87%
17.95%
14.27%
-1.58%
5.39%
7.98%
2.06%
10.42%
ROCE
15.07%
13.06%
15.21%
14.44%
12.42%
5.72%
7.92%
10.19%
5.79%
6.29%
Fixed Asset Turnover
1.23
1.38
1.26
1.09
0.92
0.81
0.84
0.82
0.78
0.70
Receivable days
51.13
48.12
51.58
59.43
54.81
49.56
46.53
47.00
48.71
53.83
Inventory Days
65.05
56.26
63.07
73.64
75.51
78.58
75.51
73.76
71.07
71.61
Payable days
53.01
55.42
56.86
54.84
53.44
52.17
51.42
45.33
38.70
50.95
Cash Conversion Cycle
63.17
48.96
57.79
78.23
76.88
75.98
70.61
75.42
81.08
74.50
Total Debt/Equity
0.83
1.01
0.85
1.18
1.51
1.95
1.67
1.71
1.69
1.81
Interest Cover
5.21
5.11
4.02
3.16
2.46
1.11
1.61
2.10
1.48
3.01

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Jubilant Pharmova’s arm enters into manufacturing partnership with Ocugen
    16th Jun 2021, 11:52 AM

    The company has entered into a manufacturing partnership for manufacturing of vaccine candidate COVAXIN for the US and Canadian markets

    Read More
  • Jubilant Pharmova’s arm to invest $92 Million to expand sterile injectable manufacturing capacity
    1st Jun 2021, 09:23 AM

    This expansion will be spread over 50,000 sq feet at the Spokane facility and will be commercially operational by the end CY24

    Read More
  • Jubilant Pharmova’s arm wins over Bracco’s legal appeals in United States Court of Appeals
    10th May 2021, 09:26 AM

    Jubilant successfully challenged Bracco’s patent infringement claims in an Inter Parties Review (IPR) proceeding before the US Patent Office as well as in a separate proceeding in the ITC

    Read More
  • Jubilant Pharmova’s arm completes studies using novel oral formulation of Remdesivir
    19th Apr 2021, 16:41 PM

    Jubilant has sought authorization for additional studies for this novel oral formulation from the Drug Controller General of India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.